Company Profile: Balt

Background

Overview

Balt is a French medical equipment manufacturer specializing in devices designed to treat stroke and other neurovascular diseases. Established in 1977 by Leopold Płowiecki, the company has grown into a global leader in neurointerventional solutions. Its mission is to develop physician-inspired innovations that provide patient-focused solutions, aiming to improve patient care through close collaboration with healthcare professionals.

Mission and Vision

Balt's mission is to develop and manufacture physician-inspired innovations, building close, responsive relationships with customers and fostering a creative, inclusive company culture to enhance patient care. The company's vision is to remain the most respected neurointerventional partner for physicians by delivering differentiated and clinically relevant solutions through excellence in execution. Balt is also focused on expanding its unique technologies to address adjacent markets with high unmet medical needs.

Industry Significance

With over 45 years of experience, Balt has been a pioneer in the field of neurointerventional devices, collaborating with physicians and institutions to develop solutions for complex conditions such as strokes, aneurysms, and arteriovenous malformations. The company offers a comprehensive portfolio of medical devices for ischemic and hemorrhagic strokes, as well as products for peripheral embolization.

Key Strategic Focus

Core Objectives

Balt aims to lead in the development of innovative neurovascular solutions, focusing on enhancing patient outcomes through minimally invasive procedures. The company is committed to expanding its global presence and addressing unmet medical needs in the neurovascular and peripheral vascular spaces.

Areas of Specialization

Balt specializes in the design and manufacture of medical devices for the interventional treatment of neurovascular diseases, including:

Microcatheters: Used for precise navigation within blood vessels.

Intracranial Stents: Provide support to cerebral arteries.

Embolization Coils: Assist in occluding blood vessels to prevent bleeding.

Flow Diverters: Redirect blood flow to promote aneurysm healing.

Thrombectomy Devices: Remove blood clots from cerebral arteries.

Key Technologies Utilized

Balt employs advanced technologies in its product development, including:

Flow Diverter Stents: Innovative devices that redirect blood flow to promote aneurysm healing.

Detachable Tip Microcatheters: Allow for precise navigation and targeted treatment within blood vessels.

Flow Directed Microcatheters: Enable accurate placement of devices within the vascular system.

Primary Markets Targeted

Balt's primary markets include:

Neurovascular Interventions: Treating conditions such as strokes, aneurysms, and arteriovenous malformations.

Peripheral Vascular Interventions: Addressing diseases affecting peripheral blood vessels.

Global Healthcare Providers: Supplying hospitals, stroke centers, and interventional radiologists or neurosurgeons worldwide.

Financials and Funding

Funding History

In 2015, Balt received a significant investment from Bridgepoint Advisers, a private equity firm, which facilitated the company's international expansion and product development.

Total Funds Raised

Specific details regarding the total funds raised by Balt are not publicly disclosed.

Recent Funding Rounds

Balt has engaged in multiple funding rounds, including debt financing, to support its growth initiatives. The most recent round occurred in January 2025, raising approximately $370 million.

Notable Investors

Bridgepoint Advisers is a notable investor in Balt, having acquired a stake in the company in 2015.

Utilization of Capital

The capital raised has been utilized for:

Product Development: Advancing the company's portfolio of neurovascular devices.

Global Expansion: Establishing a presence in over 100 countries.

Acquisitions: Including the American start-up Blockade Medical and several distributors in Europe, China, India, and Brazil.

Pipeline Development

Key Pipeline Candidates

Balt's pipeline includes:

Silk Vista Baby: The world's smallest collapsible intracranial stent, released in 2018.

OptiBlock: A novel vessel occlusion coil introduced in 2023.

Carrier Delivery Catheter: A delivery catheter introduced in 2024.

Stages of Development

These products are in various stages of development, with some already commercially available and others anticipated to launch in the near future.

Target Conditions

The pipeline targets conditions such as:

Ischemic and Hemorrhagic Strokes: Addressing acute and chronic cerebrovascular events.

Peripheral Embolization: Treating diseases affecting peripheral blood vessels.

Anticipated Milestones

Balt anticipates achieving:

Regulatory Approvals: For new products in various global markets.

Market Launches: Introducing new devices to healthcare providers worldwide.

Technological Platform and Innovation

Proprietary Technologies

Balt's proprietary technologies include:

Flow Diverter Stents: Innovative devices that redirect blood flow to promote aneurysm healing.

Detachable Tip Microcatheters: Allow for precise navigation and targeted treatment within blood vessels.

Flow Directed Microcatheters: Enable accurate placement of devices within the vascular system.

Significant Scientific Methods

Balt employs advanced scientific methods such as:

Advanced Imaging Techniques: To guide device placement and ensure optimal outcomes.

Biocompatibility Testing: Ensuring devices are safe for human use.

Clinical Trials: To validate the efficacy and safety of new products.

AI-Driven Capabilities

While specific AI-driven capabilities are not detailed, Balt's commitment to innovation suggests ongoing exploration of advanced technologies to enhance product development and patient care.

Leadership Team

Executive Profiles

Pascal Girin: President & Chief Executive Officer. Appointed CEO in late 2018, Girin has been instrumental in Balt's global expansion and product innovation.

Paul Laquerre: Chief Financial Officer. Oversees financial operations and strategic financial planning.

Jeff Sachs: Chief Legal & Compliance Officer. Manages legal affairs and ensures regulatory compliance.

Katherine Oates: Chief of Staff. Coordinates executive activities and strategic initiatives.

Eric Montalescot: Senior Vice President, Europe, Latin America, Middle East & Africa. Leads operations in these regions.

Fred Gunderman: Senior Vice President, USA. Oversees U.S. operations and market strategy.

Eric Largen: Vice President, Global R&D. Leads research and development efforts worldwide.

Ryan Solomon: Vice President, Corporate Strategy & Business Development. Drives strategic initiatives and partnerships.

Thomas Colson: Vice President, Global Quality. Ensures product quality and compliance with standards.

balt